• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

NKT Therapeutics

edit

NKT Therapeutics is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company’s mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat cancer, infectious diseases, autoimmune diseases, asthma and dermatitis.

Recent Milestones

edit

• 
  NKT Therapeutics — Names new Chief Medical Officer (10/5/10)
  Posted 10/6/10 at 4:01am via masshightech.com
• 
  NKT Therapeutics received $4M in Venture Round funding. (8/25/10)
  Posted 8/25/10 at 10:00pm via masshightech.com
• 
  NKT Therapeutics received $8M in Series A funding. (3/16/09)
  Posted 6/19/09 at 11:32pm via bizjournals.com
• 
  NKT Therapeutics added Barbara Finck as CMO.
  Posted 10/7/10 at 8:39pm

Videos

Screenshots

edit

Above: NKT Therapeutics Screenshot -- #1
Uploaded: 6/20/09

Sources

1. NKT Therapeutics launches with $8M (bizjournals.com) [edit]
2. NKT Therapeutics taps backers for $4M in new round (masshightech.com) [edit]
Finck takes top medical job at NKT Therapeutics (masshightech.com) [edit]